IsoRay, Inc.(ISR) - 2025 Q3 - Quarterly Report

PART I - FINANCIAL INFORMATION This section provides the company's unaudited condensed consolidated financial statements and management's discussion and analysis for the reporting period Item 1 - Financial Statements This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations and comprehensive loss, cash flows, and changes in stockholders' equity, along with detailed notes explaining accounting policies, significant transactions, and financial positions for the periods ended March 31, 2025, and December 31, 2024 Condensed Consolidated Balance Sheets This statement presents the company's financial position, including assets, liabilities, and equity, as of March 31, 2025, and December 31, 2024 Condensed Consolidated Balance Sheets | Metric | March 31, 2025 (unaudited) (in thousands) | December 31, 2024 (in thousands) | | :-------------------------------- | :--------------------------------------- | :------------------------------- | | Cash and cash equivalents | $44,406 | $61,580 | | Short-term investments | $167,296 | $165,336 | | Total current assets | $215,742 | $231,160 | | Total assets | $329,349 | $341,101 | | Total current liabilities | $12,679 | $18,230 | | Total liabilities | $44,704 | $50,433 | | Total stockholders' equity | $284,645 | $290,668 | Condensed Consolidated Statements of Operations and Comprehensive Loss This statement details the company's revenues, expenses, and net loss for the three months ended March 31, 2025, and 2024 Condensed Consolidated Statements of Operations and Comprehensive Loss | Metric | Three Months Ended March 31, 2025 (in thousands) | Three Months Ended March 31, 2024 (in thousands) | | :------------------------------------ | :----------------------------------------------- | :----------------------------------------------- | | Grant revenue | $342 | $325 | | Research and development expenses | $14,332 | $7,452 | | General and administrative expenses | $7,842 | $5,878 | | Total operating expenses | $22,174 | $13,330 | | Operating loss | $(21,832) | $(13,005) | | Total non-operating income, net | $3,655 | $1,180 | | Net loss | $(18,177) | $(12,284) | | Basic and diluted loss per share | $(0.25) | $(0.25) | | Weighted average shares (Basic/Diluted) | 72,357 | 49,510 | Condensed Consolidated Statements of Cash Flows This statement outlines the company's cash inflows and outflows from operating, investing, and financing activities for the three months ended March 31, 2025, and 2024 Condensed Consolidated Statements of Cash Flows | Cash Flow Activity | Three Months Ended March 31, 2025 (in thousands) | Three Months Ended March 31, 2024 (in thousands) | | :--------------------------------------- | :----------------------------------------------- | :----------------------------------------------- | | Net cash (used in) provided by operating activities | $(21,582) | $13,848 | | Net cash used in investing activities | $(5,565) | $(47,297) | | Net cash provided by financing activities | $9,973 | $166,328 | | Net (decrease) increase in cash, cash equivalents and restricted cash | $(17,174) | $132,879 | | Cash, cash equivalents and restricted cash end of period | $44,406 | $142,299 | Condensed Consolidated Statements of Changes in Stockholders' Equity This statement details changes in the company's stockholders' equity, including common stock, additional paid-in capital, and accumulated deficit, for the three months ended March 31, 2025, and 2024 Condensed Consolidated Statements of Changes in Stockholders' Equity | Metric | Balances at Dec 31, 2024 (in thousands) | Balances at Mar 31, 2025 (in thousands) | | :--------------------------------------- | :-------------------------------------- | :-------------------------------------- | | Common Stock (Shares) | 70,671,464 | 74,050,841 | | Common Stock (Amount) | $70 | $73 | | Additional Paid-in Capital | $522,368 | $534,449 | | Accumulated Other Comprehensive Income (Loss) | $(51) | $19 | | Accumulated Deficit | $(231,719) | $(249,896) | | Total Stockholders' Equity | $290,668 | $284,645 | - Issuance of common stock pursuant to the 2024 "At-the-Market Agreement" resulted in 3,379,377 shares and $9,986 thousand in total equity for the three months ended March 31, 2025[20] - Share-based compensation contributed $2,098 thousand to additional paid-in capital for the three months ended March 31, 2025, compared to $656 thousand for the same period in 2024[20] Notes to the Unaudited Condensed Consolidated Financial Statements This section provides detailed explanations of the accounting policies, significant transactions, and financial positions presented in the condensed consolidated financial statements 1. Basis of Presentation and Summary of Significant Accounting Policies This note outlines the company's reporting basis, key accounting policies, and significant events impacting financial statement presentation - The Company is a radiopharmaceutical development company focused on advanced cancer treatments[24] - The Cesium-131 brachytherapy business was sold on April 12, 2024, and its financial information is presented as discontinued operations[26] - A 1-for-10 reverse stock split was effected on June 14, 2024, with all historical per share data retroactively adjusted[27] - The Company operates as a single operating and reportable segment: radiopharmaceutical development[28] - Cash, cash equivalents, and short-term investments totaled $211.7 million as of March 31, 2025, which is believed to fund current planned operations into late 2026[29][30] 2. Loss per Share This note details the calculation of basic and diluted loss per share, including weighted average shares outstanding and potential dilutive securities - Basic and diluted loss per share for the three months ended March 31, 2025, and 2024, was $(0.25)[14] - Weighted average shares used in computing net loss per share were 72,357 thousand for 2025 and 49,510 thousand for 2024[14] Potential Dilutive Securities | Security Type | March 31, 2025 | March 31, 2024 | | :---------------------- | :------------- | :------------- | | Common stock warrants | 415,779 | 438,558 | | Common stock options | 10,170,795 | 5,164,917 | | Total potential dilutive securities | 10,586,574 | 5,603,475 | 3. Investments and Agreements This note describes significant investment and financing agreements, including equity offerings, private placements, and strategic collaborations - Under the 2024 ATM Agreement, the Company sold 3,379,377 shares of Common Stock on February 18, 2025, generating gross proceeds of approximately $10.2 million[42] - The May 2024 Registered Offering generated approximately $80.0 million in gross proceeds[44] - The March 2024 Private Placement resulted in gross proceeds of approximately $87.4 million from the sale of 9,200,998 shares of Common Stock[47] - Through the Lantheus Investment Agreement, Lantheus purchased 5,634,235 shares, representing 19.99% of outstanding Common Stock as of January 8, 2024[50] - The Company acquired Progenics' radiopharmaceutical manufacturing facility for $8.0 million in cash[54] - Lantheus paid the Company a one-time payment of $28.0 million for an exclusive option to negotiate a license for [212Pb]VMT-α-NET; $1.4 million was recognized as 'Other income from a related party' upon the expiration of certain option rights[55][58] - The January 2024 Public Offering generated approximately $69.0 million in gross proceeds[60] - Sales under the 2023 ATM Agreement on April 11, 2024, generated approximately $49.5 million in gross proceeds before its termination on August 12, 2024[64][65] 4. Discontinued Operations This note provides financial information related to the sale of the Cesium-131 brachytherapy business, presented as discontinued operations - The sale of the Cesium-131 brachytherapy business to GT Medical Technologies, Inc. was completed on April 12, 2024[66] - Consideration for the sale included 279,516 shares of GT Medical's common stock (0.5% fully diluted) and future cash royalty payments based on net sales of Cesium-131 brachytherapy seeds and GammaTile Therapy[67] Discontinued Operations Financial Summary | Metric (in thousands) | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------- | :-------------------------------- | :-------------------------------- | | Sales, net | $0 | $1,973 | | Gross profit | $0 | $571 | | Total loss from discontinued operations | $0 | $(459) | 5. Property and Equipment This note details the company's property and equipment, including recent acquisitions for future manufacturing capabilities - The Company purchased buildings in Houston, Chicago, and Los Angeles in 2024 for future manufacturing of program candidates[71] - An agreement with Comecer SpA was made to purchase manufacturing equipment for approximately €49.0 million[71] Property and Equipment, Net | Property and Equipment (in thousands) | March 31, 2025 | December 31, 2024 | | :------------------------------------ | :------------- | :---------------- | | Building | $1,770 | $1,770 | | Land | $917 | $917 | | Equipment | $11,676 | $11,423 | | Other (not placed in service) | $47,004 | $42,601 | | Property and equipment, net | $61,247 | $57,321 | 6. Other Intangible Assets This note provides information on the company's indefinite-lived intangible assets, primarily in-process research and development - Indefinite-lived intangible assets, primarily in-process research and development (IPR&D), remained at $50.0 million as of March 31, 2025, and December 31, 2024[73] - No impairment testing was deemed necessary during the three months ended March 31, 2025[73] 7. Available-for-Sale Securities This note details the composition and fair value of the company's available-for-sale securities portfolio Available-for-Sale Securities Portfolio | Security Type (in thousands) | March 31, 2025 (Fair Value) | December 31, 2024 (Fair Value) | | :--------------------------- | :-------------------------- | :----------------------------- | | Securities of U.S. government and government agencies | $48,765 | $51,500 | | Commercial paper | $40,462 | $44,473 | | Certificates of deposit | $1,725 | N/A | | Corporate debt securities | $69,370 | $64,570 | | Asset-backed securities | $6,974 | $4,793 | | Total available-for-sale securities | $167,296 | $165,336 | - Accrued interest receivable on available-for-sale securities increased from $0.2 million at December 31, 2024, to $0.9 million at March 31, 2025[76] 8. Fair Value Measurements This note provides fair value measurements for financial instruments, categorized by valuation input levels Fair Value Measurements of Financial Instruments | Category (in thousands) | March 31, 2025 (Fair Value) | December 31, 2024 (Fair Value) | | :---------------------- | :-------------------------- | :----------------------------- | | Level 1 (Money market funds) | $41,112 | $46,079 | | Level 2 (Various securities) | $167,296 | $178,977 | | Total cash equivalents and available-for-sale securities | $208,408 | $225,056 | - There were no Level 3 financial instruments measured at fair value on a recurring basis at March 31, 2025, and December 31, 2024[78] 9. Share-Based Compensation This note details share-based compensation expenses and changes in the company's equity incentive plan Share-Based Compensation Expense | Expense Category (in thousands) | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :------------------------------ | :-------------------------------- | :-------------------------------- | | Research and development expense | $897 | $263 | | General and administrative expense | $1,201 | $359 | | Total share-based compensation expense | $2,098 | $622 | - The aggregate number of shares authorized for issuance under the Amended and Restated 2020 Equity Incentive Plan increased by 4,870,092 to a total of 12,500,000 shares[80] - An additional 3,533,573 shares were registered for 2025 under the plan's "evergreen" provision[80] 10. Commitments and Contingencies This note outlines the company's legal accruals and significant purchase commitments - The Company has an accrual of $0.2 million for an estimated legal settlement as of March 31, 2025, and December 31, 2024[82] - A "take-or-pay" provision commits the Company to purchasing approximately $8.4 million of thorium-228 from the U.S. Department of Energy during 2025 and 2026[83] 11. Related Parties This note describes transactions and agreements with related parties, including investment and facility acquisition details - Lantheus purchased 5,634,235 shares of Common Stock, representing 19.99% of outstanding shares as of January 8, 2024, through the Lantheus Investment Agreement[84] - The Company acquired a manufacturing facility from Progenics, an affiliate of Lantheus, for $8.0 million[85] - Lantheus was granted an exclusive option for [212Pb]VMT-α-NET, with a one-time payment of $28.0 million; $1.4 million was recognized as 'Other income from a related party' upon the expiration of certain option rights[86][87] 12. Leases This note provides information on the company's operating lease arrangements and future payment obligations - The weighted average remaining term for operating leases was 2.9 years, and the weighted average discount rate was 8% as of March 31, 2025[94] - Operating lease expense was $0.3 million for the three months ended March 31, 2025, compared to de minimis for the same period in 2024[94] Future Operating Lease Payments | Year Ending December 31, | Future Operating Lease Payments (in thousands) | | :----------------------- | :--------------------------------------------- | | 2025 (remaining nine months) | $836 | | 2026 | $647 | | 2027 | $493 | | 2028 | $443 | | Total lease liability | $2,154 | - An estimated liability of $0.5 million for hazardous waste removal related to prior activities remains, despite the Asset Retirement Obligation for the Richland, WA facility being assigned to GT Medical[96] 13. Note Payable This note details the company's note payable, including its current and long-term portions and balloon payment schedule Note Payable Summary | Note Payable (in thousands) | March 31, 2025 | December 31, 2024 | | :-------------------------- | :------------- | :---------------- | | Note payable | $1,664 | $1,677 | | Less: current portion | $(53) | $(52) | | Note payable, long-term portion | $1,611 | $1,625 | - A balloon payment of approximately $1.5 million for the promissory note is due on December 29, 2027[97] Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations This section provides management's perspective on the company's financial condition, operational performance, and future outlook, covering clinical trial progress, manufacturing, funding, and financial analysis Overview This section introduces Perspective Therapeutics as a radiopharmaceutical development company focused on advanced cancer treatments and its key clinical programs - Perspective Therapeutics is a radiopharmaceutical development company focused on advanced cancer treatments using the alpha-emitting isotope Lead-212 (212Pb) and a theranostic approach[100] - Clinical programs VMT-α-NET (neuroendocrine tumor), VMT01 (melanoma), and PSV359 (solid tumor) are in Phase 1/2a imaging and therapy trials in the U.S[101] VMT-α-NET This section details the clinical progress of VMT-α-NET, targeting SSTR2-expressing neuroendocrine tumors with 212Pb - VMT-α-NET targets SSTR2-expressing neuroendocrine tumors (NETs) with 212Pb[102] - Phase 1/2a study in unresectable or metastatic SSTR2-positive NETs reported no dose-limiting toxicities (DLTs), grade 4 or 5 treatment-emergent or serious adverse events (AEs) in Cohorts 1 and 2[103] - Interim results showed two unconfirmed responses and one confirmed objective response in Cohort 2 as of January 10, 2025[104] - As of April 30, 2025, a total of 40 patients have begun treatment in Cohort 2[108] VMT01 This section outlines the clinical development of VMT01, targeting MC1R-overexpressed melanoma cancers with 212Pb, including Fast Track Designation and combination trials - VMT01 targets melanocortin 1 receptor (MC1R) overexpressed in melanoma cancers with 212Pb[111] - The FDA granted Fast Track Designation for the clinical development of [212Pb]VMT01 in September 2024[112] - A clinical trial collaboration with Bristol Myers Squibb is evaluating [212Pb]VMT01 in combination with nivolumab[113] - Initial results from the first two dosing cohorts showed no DLTs, no grade 4 or 5 treatment-emergent AEs, and one unconfirmed objective response in Cohort 1[114][115] - The Safety Monitoring Committee recommended exploring a lower dose level of 1.5 mCi for monotherapy and combination with nivolumab, with both cohorts now active and open for enrollment[116] PSV359 This section describes PSV359, a novel cyclic peptide targeting FAP-α, and its initial imaging results and clinical trial initiation - PSV359 is a novel cyclic peptide targeting FAP-α, a pan-cancer target expressed on tumor stroma cells and some cancer cells[117] - First-in-human SPECT/CT imaging of [203Pb]PSV359 showed strong tumor uptake, fast renal clearance, low normal organ accumulation, and long tumor retention[118] - The IND application for PSV359 was filed in December 2024, and a "study may proceed" letter was received from the FDA in Q1 2025; the first patient was treated with [212Pb]PSV359 on April 29, 2025[118] Other Pipeline Candidates This section highlights additional pipeline candidates, including in-licensed pre-targeting and PSMA Alpha-PET DoubLET platform technologies - The Company in-licensed Stony Brook University's CB7-Adma pre-targeting platform in January 2024, covering global intellectual property rights[119] - A license agreement with Mayo Clinic for the PSMA Alpha-PET DoubLET platform technology for PSMA-expressing cancers was announced in January 2024[120] Discovery Program This section describes the discovery team's efforts in developing novel constructs for potential first-in-human imaging to de-risk future therapeutic benefits - The discovery team is developing multiple novel constructs for potential first-in-human imaging to de-risk future therapeutic benefits[121] Intellectual Property (IP) This section highlights recent patent allowances for proprietary 212Pb generation technology and the VMT-α-NET compound - Two patent applications were allowed by the USPTO: one for proprietary 212Pb generation technology (expires August 2044) and another for the VMT-α-NET compound (expires January 2041)[122] Funding Requirements This section discusses the company's anticipated increase in expenses due to advancing clinical programs and its current liquidity position - The Company has incurred recurring losses and expects expenses to increase due to advancing preclinical activities, clinical trials, and potential commercialization of program candidates[123] - As of March 31, 2025, cash, cash equivalents, and short-term investments of $211.7 million are expected to fund planned operations into late 2026[123] - Management anticipates a significant increase in research and development expenses[123] Manufacturing and Supply This section outlines the company's strategy for manufacturing and supply chain, including third-party CMOs, internal sites, and key purchase commitments - The Company plans to use a combination of third-party contract manufacturing organizations (CMOs) and its own manufacturing sites for clinical supply and distribution[124] - A purchase order with the U.S. Department of Energy (DOE) commits the Company to purchasing approximately $8.4 million of thorium-228 during 2025 and 2026[125] - The Company agreed to purchase manufacturing equipment from Comecer SpA for approximately €49.0 million[126] Facility Acquisitions This section details the acquisition of manufacturing facilities in Houston, Chicago, Los Angeles, and Somerset, NJ, to support future production - Buildings were purchased in Houston, Chicago, and Los Angeles in 2024 for future manufacturing[127] - The radiopharmaceutical manufacturing facility in Somerset, NJ, acquired in 2024, achieved its first shipment and patient dosing in October 2024[128] 2024 At-the-Market (ATM) Agreement This section describes the 2024 ATM Agreement for common stock sales and the proceeds generated from recent issuances - The Company entered into a 2024 ATM Agreement to sell up to $250.0 million of common stock through ATM Agents[131] - On February 18, 2025, 3,379,377 shares were sold under the 2024 ATM Agreement, generating approximately $10.2 million in gross proceeds[135] Brachytherapy Divestiture This section details the sale of the Cesium-131 brachytherapy business, including the consideration received - The sale of the Cesium-131 brachytherapy business to GT Medical Technologies, Inc. was completed on April 12, 2024[136] - Consideration included 279,516 shares of GT Medical's common stock and future cash royalty payments based on net sales of Cesium-131 brachytherapy seeds and GammaTile Therapy[137][138] Critical Accounting Policies and Estimates This section confirms no material changes to critical accounting policies and estimates since the 2024 Form 10-K - There have been no material changes to the critical accounting policies and estimates disclosed in the 2024 Form 10-K as of March 31, 2025[139] Results of Operations This section analyzes the company's financial performance, including revenues, expenses, and operating loss, for the three months ended March 31, 2025, compared to 2024 - The Company now operates in one segment (Drug Operations) following the brachytherapy divestiture[140] Consolidated Statements of Operations Summary | Metric (in thousands) | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | Change | | :-------------------- | :-------------------------------- | :-------------------------------- | :----- | | Grant revenue | $342 | $325 | $17 | | Research and development expenses | $14,332 | $7,452 | $6,880 | | General and administrative expenses | $7,842 | $5,878 | $1,964 | | Total operating expenses | $22,174 | $13,330 | $8,844 | | Operating loss | $(21,832) | $(13,005) | $(8,827) | - The increase in research and development expenses was primarily due to expanded development of TAT drug programs, higher personnel costs, and third-party R&D fees[143] - General and administrative expenses increased primarily due to increased personnel costs, partially offset by decreased professional services fees[149] Liquidity and Capital Resources This section discusses the company's cash flows, sources of liquidity, and future funding requirements Cash Flows This section analyzes the company's cash flows from operating, investing, and financing activities Cash Flow Summary | Cash Flow Activity (in thousands) | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Net cash (used in) provided by operating activities | $(21,582) | $13,848 | | Net cash used in investing activities | $(5,565) | $(47,297) | | Net cash provided by financing activities | $9,973 | $166,328 | | Net (decrease) increase in cash and cash equivalents | $(17,174) | $132,879 | - Net cash used in operating activities in Q1 2025 was primarily due to a net loss of $18.2 million, adjusted for non-cash expenses and changes in operating assets and liabilities[151] - Net cash provided by operating activities in Q1 2024 was primarily due to $28.0 million received from an option agreement with Lantheus[152] Sources of Liquidity This section identifies the company's primary sources of capital, including various equity offerings and agreements - The 2024 At-the-Market (ATM) Agreement allows for the sale of up to $250.0 million of common stock; $10.2 million in gross proceeds were raised on February 18, 2025[157][161] - The May 2024 Registered Offering generated approximately $80.0 million in gross proceeds[162][163] - The March 2024 Private Placement with institutional investors generated approximately $87.4 million in gross proceeds[165] - The Lantheus Investment Agreement involved the sale of 5,634,235 shares to Lantheus, representing 19.99% ownership[166] - The January 2024 Public Offering generated approximately $69.0 million in gross proceeds[167][168] - Sales under the 2023 ATM Agreement on April 11, 2024, resulted in approximately $49.5 million in gross proceeds[170] Funding Requirements This section reiterates the company's anticipated increase in expenses and the need for additional capital to fund operations until profitability - Expenses are expected to increase significantly as the Company advances preclinical activities, clinical trials, and potential commercialization of program candidates[171] - Current cash, cash equivalents, and short-term investments of $211.7 million (as of March 31, 2025) are expected to fund operations into late 2026[171] - Additional capital will be required until profitability is achieved, potentially through equity offerings, debt financings, or strategic alliances, which may dilute existing stockholders[172][176] Capital expenditures This section addresses management's continuous evaluation of capital deployment for research, development, and operational support - Management continuously evaluates capital deployment for research and development and general and administrative functions to support clinical trials, preclinical activities, and product candidate supply[177] Financing activities This section outlines future capital financing strategies, including equity sales, collaborations, or debt, with potential stockholder dilution - Future capital is expected to be financed through equity sales, strategic collaborations, or debt financing, with anticipated dilution to stockholders[178] Other Commitments and Contingencies This section confirms no material changes to other commitments and contingencies beyond those previously disclosed - No material changes to other commitments and contingencies occurred during the three months ended March 31, 2025, beyond those disclosed in Note 10[179] Off-Balance Sheet Arrangements This section states that the company has no off-balance sheet arrangements - The Company has no off-balance sheet arrangements[180] Item 3 - Quantitative and Qualitative Disclosures About Market Risk As a smaller reporting company, Perspective Therapeutics, Inc. is exempt from providing quantitative and qualitative disclosures about market risk - The Company is a smaller reporting company and is not required to provide information on quantitative and qualitative disclosures about market risk[181] Item 4 - Controls and Procedures Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal control over financial reporting during the quarter - The principal executive officer and principal financial officer concluded that the design and operation of disclosure controls and procedures were effective as of March 31, 2025[182] - There have been no material changes in internal control over financial reporting during the most recent fiscal quarter[183] PART II - OTHER INFORMATION This section covers legal proceedings, risk factors, equity sales, defaults, mine safety, other information, and exhibits Item 1 - Legal Proceedings The company is not currently involved in any material legal proceedings and is unaware of any pending or threatened legal actions that could significantly impact its business, operating results, or financial condition - The Company is not currently a party to any material legal proceedings[184] - No pending or threatened legal proceedings are known that could have a material adverse effect on the business, operating results, or financial condition[184] Item 1A - Risk Factors The company refers to the comprehensive risk factors detailed in its 2024 Form 10-K and confirms that no material changes to these risk factors have occurred during the current reporting period - There have been no material changes to the risk factors disclosed in Part I, Item 1A of the 2024 Form 10-K[185] Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds The company reports no unregistered sales of equity securities or use of proceeds for the period - None[186] Item 3 - Defaults Upon Senior Securities The company reports no defaults upon senior securities for the period - None[187] Item 4 - Mine Safety Disclosures This item is not applicable to the company's operations - Not applicable[188] Item 5 - Other Information No directors or executive officers adopted, modified, or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the three months ended March 31, 2025 - No directors or executive officers adopted, modified, or terminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" during the three months ended March 31, 2025[189] Item 6 - Exhibits This section lists all exhibits filed as part of the Form 10-Q, including various agreements, certificates, and certifications - The exhibits include merger agreements, certificates of incorporation, bylaws, an executive employment agreement, and certifications from the principal executive and financial officers[191] Signatures The report is duly signed on behalf of Perspective Therapeutics, Inc. by its Chief Executive Officer and Chief Financial Officer - The report was signed by Johan (Thijs) Spoor, Chief Executive Officer, and Juan Graham, Chief Financial Officer, on May 12, 2025[193]